X0306 4 2015-02-26 0 0001279695 UNIVERSAL BIOSENSORS INC UBI 0001514822 Wright Paul 1 CORPORATE AVENUE ROWVILLE VICTORIA C3 3178 AUSTRALIA 1 1 0 0 Chief Executive Officer Common stock 2015-02-26 4 P 0 269088 99812.57 A 606516 I By Chatsworth Trust Common stock 44666 I By Macqarie Super Fund Manager Common stock 142105 I By P K W Super Fund Common stock 2957 D Stock Option (Right to Buy) 0.00 2020-12-11 Common Stock 60000 60000 D Stock Option (Right to Buy) 0.00 2019-11-12 Common Stock 37500 37500 D Stock Option (Right to Buy) 1.38 2018-02-23 Common Stock 2300000 2300000 D The prices reported are stated in Australian dollars. The reported securities are held in trust for the benefit of the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The reported securities are held by the Macquarie Super Fund Manager in a pooled superannuation fund for the account of the Reporting Person. The reported securities are held by the Macquarie Super Fund Manager in trust and for the account of the Reporting Person. On December 12, 2013, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on June 12, 2014. The stock options vest and become exercisable in three equal tranches om 12/31/14, 12/31/15 and 12/31/16. On November 13, 2012, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on May 16, 2013. The stock options vest and become exercisable in three equal tranches om 12/31/13, 12/31/14 and 12/31/15. 1,400,000 options vest in equal traunches over three years subject to continued employment at the time of vesting. 500,000 of the options vested upon the company entering into a material partnership/licensing agreement with Siemens Healthcare Diagnostics, Inc. on September 9, 2011. 400,000 options vest upon CE marketing or first regulatory approval in the United States of the final test to which the partnership/licensing arranagement relates, subject to continued employment at the time of vesting. /s/ Cameron Billingsley, attorney-in-fact 2015-03-02